High-throughput lipidomics analysis discovers lipid biomarkers and profiles as potential targets to evaluating efficacy of Kai-Xin-San against APP/PS1 transgenic mice based on UPLC-Q/TOF-MS.
Lipid metabolism has a significant function in the central nervous system and Alzheimer's disease (AD) is an age-related senile disease characterized by central nerve degeneration. The pathological development of AD is closely related to lipid metabolism disorders. To reveal the influence of Kai-Xin-San (KXS) on lipid metabolism in APP/PSI transgenic mice and potential therapeutic targets for treating AD, the brain tissue samples were collected and analyzed by high-throughput lipidomics based on UPLC-Q/TOF-MS tool. The collected raw data were processed by multivariate data analysis method to discover the potential biomarkers and lipid metabolic profiles. Compared with the control wild-type mice group, 9 potential lipid biomarkers were found in the AD model group, of which 7 were up-regulated and 2 were down-regulated. Orally administrated KXS can reverse the change of these potential biomarkers. Compared with the model group, a total of 6 differential metabolites have recovery trend and may be potential targets for KXS to treat AD. In this study, it showed that high-throughput lipidomics can discover the perturbed pathways and lipid biomarkers as potential targets to reveal the therapeutic effects of KXS.